Erastin: Benchmark Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that selectively induces ferroptosis, an iron-dependent, non-apoptotic cell death, in tumor cells with RAS or BRAF mutations (Wang et al. 2024). It acts by inhibiting the cystine/glutamate antiporter system Xc⁻ and modulating the voltage-dependent anion channel (VDAC), leading to lethal accumulation of reactive oxygen species (ROS) and lipid peroxides. Erastin is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with warming, and is optimally stored at -20°C. APExBIO's Erastin (B1524) is widely used for reproducible ferroptosis assays in cancer biology, with standard dosing at 10 μM for 24 hours in engineered or HT-1080 human tumor cells. Recent spatial transcriptome studies have confirmed ferroptosis as a distinct and critical process in disease and development, highlighting Erastin's value as a research tool (Wang et al. 2024).

Biological Rationale

Ferroptosis is a programmed cell death modality characterized by iron-dependent lipid peroxidation and depletion of glutathione peroxidase 4 (GPX4) activity (Wang et al. 2024). Unlike apoptosis or necrosis, ferroptosis does not involve caspase activation or classic morphological hallmarks. Oncogenic mutations in RAS (HRAS, KRAS) and BRAF increase tumor cell susceptibility to ferroptosis, making iron-dependent non-apoptotic cell death a promising therapeutic strategy (internal). Erastin is the reference compound for inducing ferroptosis in vitro, enabling mechanistic dissection of redox homeostasis and the role of iron metabolism in tumor biology.

Mechanism of Action of Erastin

Erastin targets two principal pathways:

• Direct inhibition of the cystine/glutamate antiporter (system Xc⁻, encoded by SLC7A11), reducing cystine uptake and depleting intracellular glutathione (GSH).
• Modulation of the voltage-dependent anion channel (VDAC) on the mitochondrial outer membrane, altering mitochondrial function and promoting ROS accumulation.

With decreased cystine import, cells are unable to synthesize GSH, impairing the cellular antioxidant defense system. This leads to the accumulation of lipid peroxides and iron-catalyzed oxidative damage, ultimately causing ferroptosis (Wang et al. 2024). The specificity for RAS/BRAF-mutant cells is linked to their altered redox and metabolic dependencies (internal), which make them more vulnerable to Erastin-induced oxidative stress. For a mechanistic deep-dive, see this article—which this dossier extends by providing quantitative solution conditions and latest transcriptome benchmarks.

Evidence & Benchmarks

• Erastin induces ferroptosis, not apoptosis or necrosis, as shown by lack of caspase activation and presence of mitochondrial shrinkage and increased lipid ROS (Wang et al. 2024, DOI).
• Selective cytotoxicity is observed in RAS/BRAF-mutant tumor cells at 10 μM Erastin for 24 hours under standard cell culture conditions (APExBIO, product page).
• System Xc⁻ inhibition by Erastin is evidenced by reduced cystine uptake and GSH depletion in treated cells (Dixon et al., 2012, DOI).
• Ferroptosis is confirmed in vivo by transcriptome profiling showing downregulation of GPX4 and upregulation of lipid peroxidation markers (Wang et al. 2024, DOI).
• Erastin is insoluble in water and ethanol but soluble in DMSO at ≥10.92 mg/mL with gentle warming (APExBIO, product page).

This article updates the translational perspective presented in "Erastin and the Future of Ferroptosis" by providing current spatial transcriptome evidence and practical solution conditions for bench workflows.

Applications, Limits & Misconceptions

Erastin is widely used in:

• Ferroptosis research: Inducing and characterizing iron-dependent, non-apoptotic cell death in cancer cells.
• Cancer biology research: Studying cell death in RAS/BRAF-mutant tumors and screening for ferroptosis-sensitizing agents.
• Oxidative stress pathway assays: Dissecting antioxidant system dependencies and redox vulnerabilities.
• Drug synergy studies: Combining Erastin with GPX4 inhibitors or iron chelators for novel cancer therapy strategies.

For a strategic overview of Erastin deployment in translational oncology, see Harnessing Ferroptosis, which this article extends with explicit solution composition, storage, and mechanistic transcriptomic evidence.

Common Pitfalls or Misconceptions

• Not effective in RAS/BRAF-wildtype cells: Erastin is less cytotoxic in tumor cells lacking RAS or BRAF mutations.
• Does not induce classical apoptosis: No significant caspase-3 cleavage is observed upon Erastin treatment (Wang et al. 2024).
• Requires fresh solution preparation: Erastin is unstable in DMSO solution for long-term storage; always prepare fresh aliquots.
• Insoluble in aqueous buffers: Attempting to dissolve Erastin directly in water or ethanol yields poor solubility and inconsistent dosing.
• Ferroptosis is iron-dependent: Iron chelators like deferoxamine can block Erastin-induced cell death, confirming specificity.

Workflow Integration & Parameters

Standardized Erastin use enhances reproducibility in ferroptosis research:

• Compound preparation: Dissolve Erastin in DMSO to ≥10.92 mg/mL with gentle warming. Avoid water and ethanol as solvents (APExBIO).
• Storage: Store solid Erastin at -20°C. Prepare fresh solutions immediately before use.
• Assay conditions: Treat engineered human tumor cells (e.g., HT-1080) at 10 μM for 24 hours under standard culture conditions (37°C, 5% CO₂, pH 7.4).
• Controls: Include iron chelator (e.g., deferoxamine) and lipid antioxidant (e.g., ferrostatin-1) as negative controls to confirm ferroptosis specificity.
• Readouts: Monitor cell viability, ROS/lipid peroxidation (e.g., C11-BODIPY), and GPX4/NQO1 expression changes.

These parameters are validated in peer-reviewed studies and APExBIO's technical documentation. For comprehensive workflow best practices, see Erastin (B1524): Benchmark Ferroptosis Inducer—this dossier supplements with transcriptomic data and newer storage guidelines.

Conclusion & Outlook

Erastin (B1524) from APExBIO remains the gold-standard tool for inducing ferroptosis in vitro and in vivo, particularly in cancer models with RAS or BRAF mutations. Robust mechanistic evidence supports its role in modulating oxidative cell death via system Xc⁻ and VDAC inhibition. As transcriptomics and single-cell analyses advance, Erastin will continue to be indispensable for dissecting ferroptosis pathways and developing new therapeutic strategies targeting redox vulnerabilities. For product specifications and ordering, visit the APExBIO Erastin page.